A comprehensive review of COVID-19 characteristics
- PMID: 32774178
- PMCID: PMC7402395
- DOI: 10.1186/s12575-020-00128-2
A comprehensive review of COVID-19 characteristics
Abstract
In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested by several symptoms, ranging from asymptomatic/mild symptoms to severe illness and death. The viral infection expanded internationally and WHO announced a Public Health Emergency of International Concern. To quickly diagnose and control such a highly infectious disease, suspicious individuals were isolated and diagnostic/treatment procedures were developed through patients' epidemiological and clinical data. Early in the COVID-19 outbreak, WHO invited hundreds of researchers from around the world to develop a rapid quality diagnosis, treatment and vaccines, but so far no specific antiviral treatment or vaccine has been approved by the FDA. At present, COVID-19 is managed by available antiviral drugs to improve the symptoms, and in severe cases, supportive care including oxygen and mechanical ventilation is used for infected patients. However, due to the worldwide spread of the virus, COVID-19 has become a serious concern in the medical community. According to the current data of WHO, the number of infected and dead cases has increased to 8,708,008 and 461,715, respectively (Dec 2019 -June 2020). Given the high mortality rate and economic damage to various communities to date, great efforts must be made to produce successful drugs and vaccines against 2019-nCoV infection. For this reason, first of all, the characteristics of the virus, its pathogenicity, and its infectious pathways must be well known. Thus, the main purpose of this review is to provide an overview of this epidemic disease based on the current evidence.
Keywords: 2019-nCoV; COVID-19; Coronavirus; Epidemic disease; SARS-CoV-2; Viruses.
© The Author(s) 2020.
Conflict of interest statement
Competing interestsThe authors declare that they have no competing interests.
Figures
Similar articles
-
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Mil Med Res. 2020. PMID: 32169119 Free PMC article. Review.
-
Modeling and tracking Covid-19 cases using Big Data analytics on HPCC system platformm.J Big Data. 2021;8(1):33. doi: 10.1186/s40537-021-00423-z. Epub 2021 Feb 15. J Big Data. 2021. PMID: 33614394 Free PMC article.
-
Current Strategies of Antiviral Drug Discovery for COVID-19.Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021. Front Mol Biosci. 2021. PMID: 34055887 Free PMC article. Review.
-
Epidemiological and clinical characteristics of fifty-six cases of COVID-19 in Liaoning Province, China.World J Clin Cases. 2020 Nov 6;8(21):5188-5202. doi: 10.12998/wjcc.v8.i21.5188. World J Clin Cases. 2020. PMID: 33269255 Free PMC article.
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
Cited by
-
End-to-end SARS-CoV-2 transmission risks in sport: Current evidence and practical recommendations.S Afr J Sports Med. 2021 Jan 15;33(1):v33i1a11210. doi: 10.17159/2078-516X/2021/v33i1a11210. eCollection 2021. S Afr J Sports Med. 2021. PMID: 39498368 Free PMC article. Review.
-
Reply to Zandi, M.; Soltani, S. Comment on "Alfassam et al. Development of a Colorimetric Tool for SARS-CoV-2 and Other Respiratory Viruses Detection Using Sialic Acid Fabricated Gold Nanoparticles. Pharmaceutics 2021, 13, 502".Pharmaceutics. 2022 Sep 6;14(9):1878. doi: 10.3390/pharmaceutics14091878. Pharmaceutics. 2022. PMID: 36145626 Free PMC article.
-
Evaluation of Free Light Chains (FLCs) Synthesis in Response to Exposure to SARS-CoV-2.Int J Mol Sci. 2022 Sep 30;23(19):11589. doi: 10.3390/ijms231911589. Int J Mol Sci. 2022. PMID: 36232891 Free PMC article.
-
Prevalence of underlying diseases in died cases of COVID-19: A systematic review and meta-analysis.PLoS One. 2020 Oct 23;15(10):e0241265. doi: 10.1371/journal.pone.0241265. eCollection 2020. PLoS One. 2020. PMID: 33095835 Free PMC article.
-
A Comprehensive In Silico Study of New Metabolites from Heteroxenia fuscescens with SARS-CoV-2 Inhibitory Activity.Molecules. 2022 Oct 29;27(21):7369. doi: 10.3390/molecules27217369. Molecules. 2022. PMID: 36364194 Free PMC article.
References
-
- Paranjpe I, Russak A, De Freitas JK, Lala A, Miotto R, Vaid A, et al. Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. medRxiv. 2020.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous